Takeda Pharmaceutical Co Ltd (SSE:4502)
円 4300 0 (0%) Market Cap: 6.48 Til Enterprise Value: 10.85 Til PE Ratio: 36.14 PB Ratio: 0.88 GF Score: 74/100

Ovid Therapeutics Inc and Takeda Pharmaceutical Co Ltd to Discuss Strategic Transaction Call Transcript

Mar 03, 2021 / 01:30PM GMT
Release Date Price: 円3815 (+5.39%)
Operator

Good morning, and welcome to the Ovid Therapeutics Conference Call. (Operator Instructions)

Please note, this event is being recorded. You may listen to a webcast replay of this call by going to the Investors section of Ovid's website. I would now like to turn the conference over to Dawn Schottlandt, Argot Partners. Please go ahead.

Dawn Schottlandt
Argot Partners, LLC - SVP

Thank you, operator. Good morning, everyone, and thank you for joining today's call to discuss the royalty license and termination agreement for OV935 announced earlier with Takeda Pharmaceuticals.

Joining me on today's call are Dr. Jeremy Levin, Chairman and Chief Executive Officer of Ovid; Dr. Amit Rakhit, President and Chief Medical Officer; Jeff Rona, Chief Business Officer; and Jason Tardio, Chief Commercial Officer.

As a reminder, during today's call, we'll be making forward-looking statements. Various remarks that we make during this call about the company's future expectations, plans and prospects constitute forward-looking statements for the purposes

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot